Head-To-Head Comparison: Alpha Cognition (NASDAQ:ACOG) vs. Eloxx Pharmaceuticals (NASDAQ:ELOX)

Eloxx Pharmaceuticals (NASDAQ:ELOX) and Alpha Cognition (NASDAQ:ACOG) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of recent ratings for Eloxx Pharmaceuticals and Alpha Cognition, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eloxx Pharmaceuticals	1	0	3	2	3.00
Alpha Cognition	0	0	5	0	3.00

Eloxx Pharmaceuticals currently has a consensus price target of $38.33, indicating a potential upside of 179.81%. Alpha Cognition has a consensus price target of $18.00, indicating a potential upside of 113.02%. Given Eloxx Pharmaceuticals’ higher possible upside, analysts plainly believe Eloxx Pharmaceuticals is more favorable than Alpha Cognition.

Insider and Institutional Ownership

2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are held by insiders. Comparatively, 8.6% of Alpha Cognition shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Eloxx Pharmaceuticals and Alpha Cognition’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eloxx Pharmaceuticals	N/A	N/A	N/A
Alpha Cognition	-153.61%	-54.60%	-43.47%

Risk and Volatility

Eloxx Pharmaceuticals has a beta of -1960.42, meaning that its stock price is 196,142% less volatile than the S&P 500. Comparatively, Alpha Cognition has a beta of 2.32, meaning that its stock price is 132% more volatile than the S&P 500.

Earnings and Valuation

This table compares Eloxx Pharmaceuticals and Alpha Cognition”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eloxx Pharmaceuticals	$6.36 million	8.70	-$5.99 million	($1.54)	-8.90
Alpha Cognition	$10.22 million	18.01	-$20.67 million	($1.10)	-7.68

Eloxx Pharmaceuticals has higher earnings, but lower revenue than Alpha Cognition. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than Alpha Cognition, indicating that it is currently the more affordable of the two stocks.

Summary

Eloxx Pharmaceuticals beats Alpha Cognition on 8 of the 14 factors compared between the two stocks.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.

About Alpha Cognition

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.